Teva Focus of FTC Investigation Over Inhaler Patents
Snowflake, Fox, Global-E Online Added to America's Conviction List: Goldman
Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes
Micron's Drop Leads Chips Lower Amid Profit Taking
Teva Pharmaceutical Indus Analyst Ratings
Micron's AI Ramp From High-bandwidth Memory Is Just Starting: Analysts
Teva Pharmaceutical Industries Launches Authorized Generic Of Victoza In United States
Monday.com Drifts Lower Amid Hedgeye New Short Idea
Semi Stocks Undergo Upgrades, Price Target Hikes on AI Demand: B Riley
Applied Materials, Lam Research in Focus as Citi Expects Chip Spending to Rise
Pagaya Scores New Outperform Rating From KBW on Value to Lenders
14 Analysts Have This To Say About Monday.Com
Monday.Com Analyst Ratings
U.S. Drug Shortages Worsen to Reach a Decade High: Report
Catalyst Watch: HP Enterprise Event, Walmart+ Week, Pure Storage Buzz, and Triple-witching Volatility
Semiconductors Hit Record Highs As Industry Reaches $6.3 Trillion: 5 Chip Stocks That Outpaced Nvidia This Week
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today
Teva Asthma Inhaler Patents Are 'Improperly Listed' in FDA Orange Book
Reported Monday June 10, 2024 "Amneal, U.S. FTC Win Order Removing Teva Inhaler Patents From FDA List" - Reuters News
Jim Cramer Is 'Worried' About Palo Alto Networks, Calls Monday.com 'Really Good'